Autologous bone marrow transplantation for pediatric Hodgkin's disease: a case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry.

Abstract

This study suggests that patients with pediatric HD have the same outcome at ABMT as their adult counterparts; however, long-term complications will need to be carefully monitored.

Single-agent high-dose melphalan followed by auto-SCT for relapsed and refractory Hodgkin lymphoma in children and adolescents

“…Published European registry data indicated an NRM rate of 11.1% for 81 pediatric patients who underwent auto-SCT for HL before 1993. 6 Interstitial pneumonitis was an important cause of death in this series. Many authors believe that with current supportive care and the use of PBSCs, early NRM rates are closer to 5%.…”

“…[2][3][4]6 More commonly used conditioning regimens in adults and children have achieved event-free survival rates between 40 and 60%. 2,[4][5][6]10,12,15 Although the NRM for those with HL treated with auto-SCT has decreased with time, the use of HDC with or without RT is not without toxicity. The NRM with CBV þ /ÀP has been reported between 23 and 26%, and when second malignancies are excluded, has been reported between 5 and 14%.…”

“…2,3 Most of the reported data describe an adult rather than a pediatric population, and the few reported pediatric series involve small numbers of patients. 2,[4][5][6] However, several studies suggest that the adult literature describing the use of auto-SCT in relapsed/refractory HL can be extrapolated to children and young adults. 1,6 Numerous HDC regimens have been used before autologous stem cell rescue.…”

“…2,[4][5][6] However, several studies suggest that the adult literature describing the use of auto-SCT in relapsed/refractory HL can be extrapolated to children and young adults. 1,6 Numerous HDC regimens have been used before autologous stem cell rescue. 2,[4][5][6][7][8][9][10][11][12] More commonly these regimens include CY, carmustine and etoposide, with or without cisplatin (CBV þ /ÀP) or BEAM.…”

“…1,6 Numerous HDC regimens have been used before autologous stem cell rescue. 2,[4][5][6][7][8][9][10][11][12] More commonly these regimens include CY, carmustine and etoposide, with or without cisplatin (CBV þ /ÀP) or BEAM. 7,10,13 The University of Calgary/Tom Baker Cancer Centre has used single-agent high-dose melphalan (HDM) as a local institutional protocol for over 20 years for adults with relapsed/refractory HL with comparable efficacy, reduced short-term morbidity and lower costs compared with more standard regimens.…”